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1. Drug discovery: a brief outline of 5000 years of history
The history of drug discovery and development is as old as some of the oldest 
human civilizations. The practice of Ayurveda in India and traditional Chinese 
medicines in China are over 5000-year-old therapeutic traditions that are still 
in practice at large. Papyrus Ebers is evidence of medicinal practice in Egypt 
about 3000 years ago [1–6]. The Greek and Roman medicines became popular 
in Europe and western Asia between ~700 BC and 200 BC [7]. The ancient Arab 
medicines were in practice to a great extent until 1500 AD and are still in use in the 
Mediterranean gulf [8, 9]. The beginning of modern era medicine can be consid-
ered from the time when Edward Jenner discovered immunization for smallpox. 
The development in the field was gradual until Sir Alexander Fleming discovered 
Penicillin in 1928; since then, the field of medicinal chemistry and drug discovery 
has flourished, and by the end of the twentieth century, it became a complex inter-
disciplinary platform primarily based on synthetic organic chemistry expanding 
into various biological specificities [10–13]. As a result, the global pharmaceutical 
market strengthened to nearly 400 billion US dollars by the year 2001 [14, 15].
2. Modern-day fabric of pharmaceutical industry
At the beginning of the twenty-first century, drug discovery research faced 
new challenges transforming the classical concept of drug development that was in 
practice for half a century. With advances in science and technology, the pharma-
ceutical, health care, and IT industry, accompanied by high-pace shifts in the global 
economy, bolstered the process of modern-day drug discovery and development to 
a large significance. Novel interdisciplinary research involving metal and polymer 
nanoparticles, liposomes, antibodies, and neo-antibiotics in both academia and 
industries have opened venues for precision diagnosis, targeted drug delivery, 
and innovative immunotherapy [16–24]. Although the classical steps in drug 
discovery (involving target validation, lead molecule design, chemical synthesis, 
pre-clinical evaluation, ADME, clinical trials and development for market of the 
pharmaceutical agents) are followed to date, the distribution of funding at each 
stage have changed due to the changing global market and healthcare policies [25]. 
Even though pharmaceutical companies relatively survived the recession phase 
of the early twenty-first century, a significant amount of budget cuts in R&D and 
new drug development pipeline was evident [26]. Post-recession, in the course 
of recovery, the collaborative efforts of the pharmaceutical and IT industry have 
brought state-of-the-art analytical tools that can pull multifaceted data in large 
quantities and predict the patients’ needs and market trends [27]. This has enabled 
Drug Discovery and Development - New Advances
2
the pharmaceutical companies to reorganize the drug discovery and development 
programs in a more efficient and cost-effective way. Furthermore, market research 
has contributed to global pharmaceutical growth that is projected to reach 1.18 
trillion US dollars by 2024 [28].
The main reason of this success is the data-driven integration of every major 
component of pharmaceutical industries with the healthcare industries that 
includes hospitals, doctors, patients, and insurance companies along with the 
regular drug discovery units. This has transformed the classical linear drug discov-
ery road (Figure 1) into a complex multidimensional map (Figure 2), where the 
whole industry is revolving around the power of the market analysis in a symbiotic 
fashion. Though the specific needs of different companies are different depending 
on their size, resources, and target market, the cumulative fabric of symbiosis is 
common [29]. The existing market data has accelerated the process of “new target 
identification.” It has also helped in repurposing existing and abandoned therapeu-
tics from different phases of drug development in an unprecedented way [30, 31]. 
Proper analysis of healthcare data and labor market research have shown positive 
impact on government policies in allotting and redistributing funds for healthcare 
industries and basic academic research that are closely associated to drug discovery 
research, which consequently helps the pharmaceutical market to grow [32, 33]. 
The huge success in genomics research, high-throughput screening (HTS) robotics, 
and gene sequencing technologies resulted a pull of publication that have reported 
synthesis or extraction of a cumulative of over 90 million drug-like compounds 
[34]. Moreover, advances in large-scale cell and tissue imaging have enabled precise 
location determination of the drugs and measured variety of phenotypes in cells 
and whole organism [35]. These advances in hardware instruments, research 
methodologies, and data processing synergistically contribute at various stages 
of drug development. The application of deep learning in leveraging these large-
scale heterogeneous database is now an integral part of industrial pharmaceutical 
research [36]. Although machine learning (ML) is at its infant stage, it has already 
Figure 1. 
Classical components of drug discovery.
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reduced the library sizes for HTS and helped to understand complex multiomic data 
[37, 38]. The rapid progress of different ML methods will have considerable impact 
on future therapies [39].
3. Importance of PK/PD in modern-day drug discovery
The historical prototype for clinical drug development was to conduct a few 
Phase 1 studies followed by a couple of Phase 2 studies consequently leading to 
multiple expensive Phase 3 trials to demonstrate the efficacy of the drug candidate. 
With the changing landscape and regulatory requirements, the number of  clinical 
studies to elucidate multiple questions related to drug properties such as the 
mechanism of actions, pharmacokinetics (PK), pharmacodynamics (PD), and drug 
metabolism increased overwhelmingly prior to Phase 3 studies. The increase in the 
number of clinical trials has made drug development more lengthy and exorbitant. 
To overcome this limitation and reach patients promptly, it is imperative to utilize 
advanced technologies and approaches. One such approach is the PK/PD guided 
drug development. PK/PD modeling has been extensively employed to generate 
first-in-human dose predictions and selecting optimal doses for Phase 2 and Phase 
3 trials. PK/PD modeling also plays an instrumental role in identifying if any dose 
adjustments are needed in special populations such as pediatrics and geriatrics and 
patients with hepatic or renal impairments [40, 41]. Additionally, PK/PD model-
informed drug development (MIDD) has gained increasing momentum in recent 
years and is extensively used across pharmaceutical industries globally.
MIDD has become a crucial tool after receiving formal recognition in 
Prescription Drug User Fee Act (PDUFA) VI, thus paving a path forward to opti-
mize drug dosing prior to approval and post-marketing and in special populations 
Figure 2. 
Modern-day symbiotic fabric of drug discovery.
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in the absence of dedicated clinical trials. Dose optimization and clinical trial design 
have been most established domains of MIDD; new technologies such as artificial 
intelligence, ML, and real-world data (RWD), wearables along data science, have 
the potential to transform MIDD.
ML approaches provide a set of tools that can improve decision-making for 
well-specified questions with abundant, high-quality data. While using ML in the 
early stages of drug design, target selection, and high-throughput screening is 
almost standard today, the potential of ML during drug development has not been 
recognized. The observed data/evidence obtained during the developmental phase 
does not necessarily answer all the questions; thus the scope of MIDD is largely 
expanded with analysis of RWD to generate real-world evidence (RWE) to resolve 
these unanswered questions. Although RWD is obtained under less-controlled 
settings requiring proper interpretation of the findings, it should be considered as 
an attractive tool appealing for MIDD [42].
The emerging new techniques, such as portable devices, wearables, and applica-
tions (apps), may improve the dosing accuracy for patients and the quality of the 
collected medical information in real-world medical practice. These tools may 
improve the quality of electronic health records, making real-world data a reliable 
source for drug development and dose optimization or individualization. All these 
tools will make real-world data/real-world evidence a more appealing source for 
MIDD [43].
Along with the power of data analytics, advances in computational chemis-
try, and new diagnostic techniques, PK/PD modeling tools have also influenced 
the drug discovery research and development. These advances assist to build a 
comprehensive protein-receptor database, thereby enabling a defined library size 
for designing and optimization of a lead molecule. Along with the classical small 
molecule drug discovery and development, many protein and antibody-based 
pharmaceuticals have appeared as blockbuster drugs.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
5Introductory Chapter: The Modern-Day Drug Discovery
DOI: http://dx.doi.org/10.5772/intechopen.90922
[1] Sharma T, Rawal G. Role of 
ayurveda in tumorigenesis: A brief 
review. International Journal of Green 
Pharmacy (IJGP). 2012;6(2):93-101
[2] Mamtani R, Mamtani R. 
Ayurveda and yoga in cardiovascular 
diseases. Cardiology in Review. 
2005;13(3):155-162
[3] Khan S, Balick MJ. Therapeutic plants 
of Ayurveda: A review of selected clinical 
and other studies for 166 species. The 
Journal of Alternative & Complementary 
Medicine. 2001;7(5):405-515
[4] Glazier A. A landmark in the 
history of Ayurveda. The Lancet. 
2000;356(9235):1119
[5] Farquhar J. Knowing Practice: The 
Clinical Encounter of Chinese Medicine. 
London: Routledge; 2018
[6] Law BYK, Wu AG, Wang MJ, 
Zhu YZ. Chinese medicine: A hope 
for neurodegenerative diseases? 
Journal of Alzheimer’s Disease. 
2017;60(s1):S151-S160
[7] Ackerknecht EH, Haushofer L. A 
Short History of Medicine. Baltimore: 
Johns Hopkins University Press; 2016
[8] Saad B, Azaizeh H, Said O. Tradition 
and perspectives of Arab herbal 
medicine: A review. Evidence-based 
Complementary and Alternative 
Medicine. 2005;2(4):475-479
[9] Bynum W, Porter R. Arab-Islamic 
medicine. In: Companion Encyclopedia 
of the History of Medicine. London: 
Routledge; 2013. pp. 702-753
[10] Cates J, Christie R. Subacute 
bacterial endocarditis. A review of 442 
patients treated in 14 Centres appointed 
by the penicillin trials Committee of the 
Medical Research Council. Quarterly 
Journal of Medicine. 1951;20(78):93-130
[11] Duggleby HJ, Tolley SP, Hill CP, 
Dodson EJ, Dodson G, Moody PC. 
Penicillin acylase has a single-amino-
acid catalytic centre. Nature. 
1995;373(6511):264
[12] Heath JR, Ribas A, Mischel PS. 
Single-cell analysis tools for drug 
discovery and development. Nature 
Reviews Drug Discovery. 2016;15(3):204
[13] Kelm JM, Lal-Nag M, Sittampalam  
GS, Ferrer M. Translational in vitro 
research: Integrating 3D drug discovery 
and development processes into the 
drug development pipeline. Drug 
Discovery Today. 2019;24(1):26-30
[14] Walker N. Impacts of Glocalization 
on the Pharmaceutical Industry. 
2019. Available from: https://www.
pharmasalmanac.com/articles/
impacts-of-glocalization-on-the-
pharmaceutical-industry
[15] Pharmaceutical market: Worldwide 
revenue 2001-2018. 2019. Available 
from: https://www.statista.com/
statistics/263102/pharmaceutical-
market-worldwide-revenue-since-2001
[16] Yaari Z, Da Silva D, Zinger A, 
Goldman E, Kajal A, Tshuva R, et al. 
Theranostic barcoded nanoparticles for 
personalized cancer medicine. Nature 
Communications. 2016;7:13325
[17] Lee H, Lee Y, Song C, Cho HR, 
Ghaffari R, Choi TK, et al. An endoscope 
with integrated transparent 
bioelectronics and theranostic 
nanoparticles for colon cancer treatment. 
Nature Communications. 2015;6:10059
[18] Karmakar P, Lee K, Sarkar S, 
Wall KA, Sucheck SJ. Synthesis of a 
liposomal MUC1 glycopeptide-based 
immunotherapeutic and evaluation of 
the effect of L-rhamnose targeting on 
cellular immune responses. Bioconjugate 
Chemistry. 2015;27(1):110-120
References
Drug Discovery and Development - New Advances
6
[19] Karmakar P, Gaitonde V. Promising 
recent strategies with potential 
clinical translational value to combat 
antibacterial resistant surge. Medicine. 
2019;6(1):21
[20] Catalano JG, Gaitonde V, Beesu M, 
Leivers AL, Shotwell JB. Phenoxide 
leaving group SNAr strategy for the 
facile preparation of 7-amino-3-aryl 
pyrazolo [1, 5-a] pyrimidines from a 
3-bromo-7-phenoxypyrazolo [1, 5-a] 
pyrimidine intermediate. Tetrahedron 
Letters. 2015;56(44):6077-6079
[21] Nishimura Y, Gautam R, Chun T-W, 
Sadjadpour R, Foulds KE, Shingai M, 
et al. Early antibody therapy can induce 
long-lasting immunity to SHIV. Nature. 
2017;543(7646):559
[22] Gaitonde V, Sucheck SJ. 
Antitubercular drugs based on 
carbohydrate derivatives. Carbohydrate 
Chemistry: State of the Art and 
Challenges for Drug Development: An 
Overview on Structure, Biological Roles, 
Synthetic Methods and Application as 
Therapeutics. 2015:441-478
[23] Thanna S, Lindenberger JJ, 
Gaitonde VV, Ronning DR, Sucheck SJ. 
Synthesis of 2-deoxy-2, 2-difluoro-α-
maltosyl fluoride and its X-ray structure 
in complex with Streptomyces coelicolor 
GlgEI-V279S. Organic & Biomolecular 
Chemistry. 2015;13(27):7542-7550
[24] Hossain MK, Vartak A, Karmakar P, 
Sucheck SJ, Wall KA. Augmenting vaccine 
immunogenicity through the use 
of natural human anti-rhamnose 
antibodies. ACS Chemical Biology. 
2018;13(8):2130-2142
[25] Gilliland CT, Zuk D, Kocis P, 
Johnson M, Hay S, Hajduch M, et al. 
Putting translational science on to a 
global stage. Nature Reviews Drug 
Discovery. 2016;15(4):217
[26] Clark JW. Financial Narratives of 
US Biotechnology Companies Before, 
During, and After the Great Recession. 
2015. Available from: https://fisherpub.
sjfc.edu/cgi/viewcontent.cgi?article=1
218&context=education_etd; https://
fisherpub.sjfc.edu/education_etd/217
[27] Joshi RR, Sonavane U, Jani V, 
Saxena A, Koulgi S, Uppuladinne M, 
et al. Turbo Analytics: Applications of 
Big Data and HPC in Drug Discovery. In 
Structural Bioinformatics: Applications 
in Preclinical Drug Discovery 
Process. Switzerland: Springer; 2019. 
pp. 347-374
[28] EvaluatePharma World Preview 
2019, Outlook to 2024. 2019. Available 
from: https://www.evaluate.com/
thought-leadership/pharma/
evaluatepharma-world-preview-2019-
outlook-2024
[29] Wagner JA, Dahlem AM, 
Hudson LD, Terry SF, Altman RB, 
Gilliland CT, et al. Application of 
a dynamic map for learning, 
communicating, navigating, and 
improving therapeutic development. 
Clinical and Translational Science. 
2018;11(2):166-174
[30] Karaman B, Sippl W. Computational 
drug repurposing: Current trends. 
Current Medicinal Chemistry. 
2019;26(28):5389-5409
[31] Nordon G, Koren G, Shalev V, 
Horvitz E, Radinsky K. Proceedings 
of the AAAI Conference on Artificial 
Intelligence. Separating Wheat from 
Chaff: Joining Biomedical Knowledge 
and Patient Data for Repurposing 
Medications. Vol. 33, No 01: AAAI-19, 
IAAI-19, EAAI-20; 2019. IAAI Technical 
Track: Emerging Papers. Available from: 
https://www.aaai.org/ojs/index.php/
AAAI/article/view/5017
[32] Cinaroglu S. Politics and health 
outcomes: A path analytic approach. 
The International Journal of 
Health Planning and Management. 
2019;34(1):e824-e843
7Introductory Chapter: The Modern-Day Drug Discovery
DOI: http://dx.doi.org/10.5772/intechopen.90922
[33] Zolbanin HM, Delen D, Sharma SK. 
The strategic value of big data analytics 
in health care policy-making. 
International Journal of E-Business 
Research (IJEBR). 2018;14(3):20-33
[34] Kim S. Getting the most out 
of PubChem for virtual screening. 
Expert Opinion on Drug Discovery. 
2016;11(9):843-855
[35] Boutros M, Heigwer F, 
Laufer C. Microscopy-based 
high-content screening. Cell. 
2015;163(6):1314-1325
[36] David L, Arús-Pous J, Karlsson J, 
Engkvist O, Bjerrum EJ, Kogej T, et al. 
Applications of deep-learning 
in exploiting large-scale and 
heterogeneous compound data in 
industrial pharmaceutical research. 
Frontiers in Pharmacology. 2019;10:1-16
[37] McGaughey GB, Sheridan RP, Bayly CI, 
Culberson JC, Kreatsoulas C, Lindsley S, 
et al. Comparison of topological, shape, 
and docking methods in virtual 
screening. Journal of Chemical 
Information and Modeling. 
2007;47(4):1504-1519
[38] Johnson KW, Shameer K, Glicksberg 
BS, Readhead B, Sengupta PP, 
Björkegren JL, et al. Enabling precision 
cardiology through multiscale biology 
and systems medicine. JACC: Basic to 
Translational Science. 2017;2(3):311-327
[39] Ekins S, Puhl AC, Zorn KM, 
Lane TR, Russo DP, Klein JJ, et al. 
Exploiting machine learning for end-to-
end drug discovery and development. 
Nature Materials. 2019;18(5):435
[40] Bonate PL, Howard DR. 
Pharmacokinetics in Drug 
Development: Problems and Challenges 
in Oncology. Vol. 4. Switzerland: 
Springer; 2016
[41] Katherine Dunnington NB, 
Brandquist C, Cardillo-Marricco N, 
Di Spirito M, Grenier J. Application 
of Pharmacokinetics in Early Drug 
Development. Rijeka: IntechOpen; 2018
[42] Marshall S, Madabushi R, Manolis E, 
Krudys K, Staab A, Dykstra K, et al. 
Model-informed drug discovery 
and development: Current industry 
good practice and regulatory 
expectations and future perspectives. 
CPT: Pharmacometrics & Systems 
Pharmacology. 2019;8(2):87-96
[43] Wang Y, Zhu H, Madabushi R, 
Liu Q , Huang SM, Zineh I. Model-
informed drug development: Current 
US regulatory practice and future 
considerations. Clinical Pharmacology 
& Therapeutics. 2019;105(4):899-911
